earli
decemb
novel
coronaviru
first
report
caus
lethal
pneumonia
human
persontoperson
transmiss
demonstr
soon
wuhan
capit
citi
hubei
provinc
china
viru
rapidli
spread
china
mani
countri
global
march
viru
result
laboratoryconfirm
case
coronaviru
diseas
death
countri
world
health
organ
declar
public
health
emerg
intern
concern
given
high
risk
assess
global
level
recent
report
china
show
median
incub
period
infect
day
interquartil
rang
fever
cough
fatigu
common
symptom
sever
case
could
rapidli
progress
acut
respiratori
distress
syndrom
ard
septic
shock
abnorm
chest
comput
tomographi
particularli
groundglass
opac
bilater
patchi
shadow
found
patient
patient
lymphopenia
patient
elev
creactiv
protein
current
diagnosi
infect
almost
sole
depend
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
detect
viral
rna
use
polymeras
chain
reaction
pcr
base
technic
unfortun
sensit
rna
test
realworld
satisfi
particularli
sampl
collect
upper
respiratori
tract
use
wuhan
overal
posit
rate
rna
test
estim
around
patient
come
hospit
furthermor
overal
throughput
avail
rna
test
highli
limit
natur
requir
high
workload
need
skill
oper
test
sampl
collect
need
costli
instrument
special
oper
place
result
conveni
serolog
detect
expect
help
howev
current
knowledg
antibodi
respons
infect
limit
diagnosi
valu
antibodi
test
remain
clearli
demonstr
mani
patient
would
rais
antibodi
respons
long
antibodi
convert
posit
sinc
exposur
meaning
differ
patient
short
long
incub
period
sensit
antibodi
detect
patient
differ
ill
stage
tempor
associ
antibodi
respons
declin
viral
load
order
answer
question
investig
characterist
antibodi
respons
patient
hospit
period
detect
total
antibodi
igm
igg
use
immunoassay
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
fever
andor
respiratori
symptom
abnorm
lung
imag
find
posit
result
nucleic
acid
degre
sever
patient
categor
critic
case
bellow
clinic
scene
appear
ard
oxygen
satur
need
mechan
ventil
either
invas
noninvas
shock
complic
organ
function
failur
need
intens
care
unit
support
patient
meet
criteria
defin
noncrit
case
studi
enrol
total
case
patient
admit
hospit
jan
feb
will
donat
blood
sampl
enrol
case
confirm
infect
realtim
rtpcr
rrtpcr
test
date
ill
onset
clinic
classif
rna
test
result
hospit
period
person
demograph
inform
obtain
clinic
record
total
healthi
peopl
enrol
local
commun
studi
review
approv
medic
ethic
committe
first
affili
hospit
zhejiang
univers
approv
number
written
inform
consent
obtain
enrol
subject
total
antibodi
ab
igm
antibodi
igg
antibodi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
plasma
sampl
test
use
three
enzym
link
immunosorb
assay
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
perform
l
sampl
pipet
onto
sampl
receiv
zone
follow
ad
two
drop
sampl
buffer
lfiaigg
sampl
dilut
sampl
buffer
l
dilut
ad
onto
sampl
receiv
area
fifteen
minut
later
sampl
ad
result
lfia
observ
eye
record
incub
period
defin
interv
earliest
date
exposur
earliest
date
symptom
onset
nonnorm
distribut
continu
data
describ
median
interquartil
rang
iqr
compar
wilcoxon
test
categor
data
summar
count
percentag
confid
interv
sensit
specif
estim
binomi
exact
test
categor
data
compar
use
patient
involv
set
research
question
outcom
measur
involv
design
implement
studi
dissemin
group
possibleapplic
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
among
total
case
patient
admit
hospit
feb
patient
enrol
studi
tabl
median
age
patient
year
iqr
year
femal
critic
patient
significantli
older
noncrit
patient
p
time
exposur
onset
patient
critic
case
determin
accord
unambigu
close
contact
confirm
patient
epidemiolog
inspect
admiss
hospit
incub
period
rang
day
median
day
iqr
day
februari
total
patient
noncrit
case
recov
discharg
hospit
none
die
total
patient
healthi
peopl
test
antibodi
use
differ
immunoassay
seroconvers
rate
ab
igm
igg
patient
respect
tabl
last
blood
sampl
patient
seroconvert
collect
day
post
onset
dpo
ab
igm
igg
test
perform
elisa
seem
best
although
differ
gener
signific
therefor
follow
serolog
analys
base
result
elisa
unless
specif
note
seroconvers
sequenti
appear
ab
igm
igg
median
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
exposur
assign
short
incub
period
group
remain
patient
assign
long
incub
period
group
tabl
signific
differ
age
viral
load
earli
stage
ill
risk
critic
statu
group
howev
median
seroconvers
time
shorter
short
incub
period
group
long
incub
period
group
vs
p
contrast
median
seroconvers
day
post
onset
longer
short
incub
period
group
long
incub
period
present
studi
show
near
patient
convert
seroposit
ill
cours
seroconvers
first
observ
first
detect
antibodi
total
antibodi
follow
igm
igg
median
seroconvers
time
similar
observ
infect
interestingli
rise
antibodi
level
accompani
declin
viral
load
current
quarantin
period
set
day
sinc
close
contact
confirm
infect
case
proport
infect
could
screen
rna
test
quarantin
period
remain
unknown
howev
document
close
contactor
present
symptom
caus
transmiss
deisol
believ
antibodi
test
might
improv
sensit
find
infect
evid
shown
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
data
show
cumul
seroconvers
rate
indic
half
carrier
could
screen
antibodi
test
deisol
cumul
seroconvers
rate
reach
recent
guan
et
al
report
median
time
onset
symptom
need
mechan
ventil
support
day
therefor
time
diagnosi
admit
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
hospit
within
might
crucial
lower
fatal
infect
zhao
et
al
report
overal
rna
posit
rate
lower
patient
first
week
post
symptom
onset
fall
next
week
mani
report
indic
lot
patient
final
diagnos
rna
test
day
day
repeat
sampl
test
mani
case
strongli
epidemiolog
link
exposur
typic
lung
radiolog
find
remain
rna
neg
studi
rna
posit
rate
admit
hospit
exclud
patient
miss
diagnosi
due
undetect
viral
rna
anoth
reason
rel
high
rna
posit
rate
studi
use
deep
sputum
sampl
rna
test
contrast
conveni
popular
throatnas
swab
mani
hospit
suggest
lower
respiratori
sampl
deep
sputum
bronchoalveolar
lavag
might
reliabl
rna
detect
similar
rna
test
neg
antibodi
find
earli
stage
ill
could
exclud
possibl
infect
studi
show
seroconvers
rate
reach
increas
next
week
rel
long
window
period
seroconvers
indic
search
previous
expos
patient
subclin
carrier
specif
serolog
replac
rna
detect
could
import
complement
furthermor
fact
near
patient
convert
antibodi
posit
titer
increas
rapidli
underlin
usag
antibodi
test
confirm
exclud
diagnosi
infect
convalesc
sampl
test
present
data
show
sensit
total
antibodi
detect
higher
igm
igg
p
specif
overal
compar
studi
antibodi
test
base
elisa
cmia
lfia
valid
show
good
perform
overal
cmia
take
advantag
automaticoper
rapid
highthroughput
object
quantit
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
lfia
later
flow
immunoassay
combin
sensit
calcul
base
posit
find
assay
combin
specif
calcul
base
neg
find
assay
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
day
post
onset
antibodi
convert
median
iqr
viral
load
measur
use
ct
valu
real
time
rtpcr
detect
first
avail
sputum
sampl
collect
onset
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
